Chimeric Antigen Receptor (CAR) T-cell Therapy Market Overview: 2022-28
Base Year: 2021
Historical Years: 2017-20
Forecast Years: 2022-27
The Chimeric Antigen Receptor (CAR) T-cell Therapy Market is projected to register exponential CAGR during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the burgeoning adoption of CAR T-cell therapy to address the rising patient pool for blood cancers, including lymphomas, certain forms of leukemia, & also multiple myeloma, on account of the mounting awareness regarding its benefits over traditional treatments.
Markntel Advisor’s Chimeric Antigen Receptor (CAR) T-cell Therapy Market Insights report provides the current and forecast market analysis, individual leading companies’ market shares, challenges, Chimeric Antigen Receptor (CAR) T-cell Therapy Market drivers, barriers, Chimeric Antigen Receptor (CAR) T-cell Therapy Market Trends, and Key Players in Chimeric Antigen Receptor (CAR) T-cell Therapy Market.
Download a sample copy of the Report: https://www.marknteladvisors.com/query/request-sample/car-t-cell-therapy-market.html
✅In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.
Chimeric Antigen Receptor (CAR) T-cell Therapy Market Dynamics: 2022-27
Mounting Incidence of B-Cell Lymphoma & Improved Prognosis using Advanced Therapeutics: The growing patient pool for blood cancers, especially B-cell lymphomas, i.e., instigating the need for better clinical & therapeutic patient outcomes in refractory or relapsed cases, is the prime aspect projected to drive the Global Chimeric Antigen Receptor (CAR) T-cell Therapy Market during 2022-27. Moreover, rigorous R&D activities in developing efficient therapeutics for Non-Hodgkin Lymphoma have led to an overall improved prognosis. It, in turn, is driving more individuals toward adopting advanced treatments, which further projects remunerative prospects for the global market over the forecast years.
Browse Full Report with Detail Analysis – https://www.marknteladvisors.com/research-library/car-t-cell-therapy-market.html
Chimeric Antigen Receptor (CAR) T-cell Therapy Market (2022-27): Segmentation Outlook
The market report has segmented the market into the following categories:
· Drug Class
o Yescarta (axicabtagene ciloleucel)
o Kymriah (tisagenlecleucel)
o Tecartus (brexucabtagene autoleucel)
o Breyanzi (lisocabtagene maraleucel)
o Others (Abecma (Idecabtagene vicleucel), etc.)
According to report, Amongst all drugs, Yescarta holds the largest share in the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, and the same trend is likely to be followed during 2022-27.
· By Application
o Acute Lymphocytic Leukemia (ALL)
o Diffuse Large B-cell Lymphoma (DLBCL)
o Follicular Lymphoma
o Multiple Myeloma
o Others (Mantle Cell Lymphoma, etc.)
According to report, Here, Diffuse Large B-cell Lymphoma (DLBCL), followed by Acute Lymphocytic Leukemia (ALL), dominates the market with the largest share.
· By End-User
o Hospitals
o Clinics
o Specialty Cancer Centers
· By Region
o North America
o South America
o Europe
o Middle East & Africa
o Asia-Pacific
Note – If there are any particular details you need that are not currently included in the report, we will be happy to provide them as part of our customization services.
Top Companies Operating in the Chimeric Antigen Receptor (CAR) T-cell Therapy Market:
- Amgen Inc.
- Bluebird Bio, Inc.
- Bristol Myers Squibb
- CARsgen Therapeutics
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
- Sorrento Therapeutics, Inc.
- Others
Reports Delivery Format – Market research studies from MarkNtel Advisors are offered in PDF, Excel, and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address
About Us –
We are a leading market research company, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.
Contact Us –
Email: sales@marknteladvisors.com
Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Address Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
